Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) reported that it recorded total revenues of $997,515 and a net loss of $3,740,494 or ($0.03) per share for the three month period ended June 30, 2008.
Corporate Update
"We have made tremendous progress in the second quarter of 2008," said S. Wayne Kay, Chief Executive Officer. "Our announced strategic partnership with Roche Diagnostics, the largest in vitro diagnostics company in the world, to commercialize our cardiovascular tests and new RAMP 200 Reader solidifies our commercialization strategy. Coupled with our partnerships with 3M and Shionogi, we believe we are poised for rapid market expansion of our RAMP platform."
"The key to Roche's marketing launch for the cardiovascular line of products was for us to receive the U.S. FDA clearance of the NT-proBNP assay for the diagnosis of heart failure. Subsequent to the end of the second quarter we received this clearance, paving the way for an expected launch of the cardiovascular product line on the new RAMP 200 analyzer in the first quarter of 2009."
"Roche is very focused on training their extensive sales force and we are preparing for the manufacture of the large number of co-branded Readers and test kits to support that launch. The global POC cardiac market is expanding dramatically and Roche will be putting the resources in place to take advantage of this opportunity." -- www.cnxmarketlink.com
Comment and add to the story without registration, but keep the comments meaningful please. Links are not accepted.
